Introduction
Chronic exposure to inorganic arsenic (iAs) has been associated with the development of multiple disorders including cancer, cardiovascular disease, neurological dysfunction, and traits of metabolic syndrome, including impaired glucose homeostasis (Wang et al. 2007; Paul et al. 2011; Martinez et al. 2011; Moon et al. 2012; Tyler and Allan 2014) . In 2011, a National Toxicology Program (NTP) expert panel reviewed published data on the association between chronic exposure to iAs in drinking water and diabetes. While the panel concluded that there was sufficient evidence to link chronic, high-level exposure to iAs (> 150 ppb) with risk of diabetes (Maull et al. 2012 ), additional mechanistic studies were recommended to determine the causal relationship between iAs exposure and diabetes as well as to identify mechanisms underlying the Abstract Growing evidence suggests that exposure to environmental contaminants contributes to the current diabetes epidemic. Inorganic arsenic (iAs), a drinking water and food contaminant, is one of the most widespread environmental diabetogens according to epidemiological studies. Several schemes have been proposed to explain the diabetogenic effects of iAs exposure; however, the exact mechanism remains unknown. We have shown that in vitro exposure to low concentrations of arsenite (iAs III ) or its trivalent methylated metabolites, methylarsonite (MAs III ) and dimethylarsinite (DMAs III ), inhibits glucose-stimulated insulin secretion (GSIS) from isolated pancreatic islets, with little effect on insulin transcription or total insulin content. The goal of this study was to determine if exposure to trivalent arsenicals impairs mitochondrial metabolism, which plays a key role in the regulation of GSIS in β cells. We used a Seahorse extracellular flux analyzer to measure Electronic supplementary material The online version of this article (doi:10.1007/s00204-017-2074-y) contains supplementary material, which is available to authorized users.
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pancreatic β-cell dysfunction and insulin resistance that were reported in individuals exposed to iAs.
In 2013, we showed that in vitro exposure to arsenite (iAs III ) inhibits glucose-stimulated insulin secretion (GSIS) in isolated murine pancreatic islets with little or no effect on insulin mRNA level or insulin content, suggesting a defect in the insulin secretory machinery rather than in insulin synthesis (Douillet et al. 2013) . We also examined GSIS in islets exposed to the trivalent methylated metabolites of iAs, methylarsonite (MAs III ) and dimethylarsinite (DMAs III ), and found that these metabolites are more potent inhibitors of GSIS than iAs III . These data imply that the metabolism of iAs can impact its diabetogenic potential, thus adding a layer of complexity to the association between iAs exposure and the risk of developing diabetes. Although this and other studies provide evidence linking iAs exposure to inhibition of insulin secretion in pancreatic islets, the molecular mechanisms behind this effect remain largely unknown.
Insulin secretion by β cells is a complex process that involves multiple steps, starting with the uptake and oxidation of glucose and production of pyruvate by glycolysis. Pyruvate is shuttled into the mitochondria where it serves as a substrate for the energy (ATP) producing pathways, which are dependent on mitochondrial respiration. ATP generated in these pathways is responsible for the closure of ATP-sensitive potassium channels, leading to β-cell membrane depolarization, calcium influx, and insulin exocytosis (Fu et al. 2013) . Thus, optimal mitochondrial function, which is coupled with the oxygen consuming electron transport chain in the inner mitochondrial membrane, is critically important for insulin secretion by the β cell (Maechler 2013) . In 2010, Fu and co-workers observed a minor, but statistically significant reduction in oxygen consumption in glucose-stimulated INS-1 832/13 β cells exposed to iAs III , suggesting a possible impairment in mitochondrial metabolism and ATP production (Fu et al. 2010 ). Our present study builds on these findings by examining the rate of oxygen consumption in INS-1 832/13 β cells exposed not only to iAs III , but also to its methylated trivalent metabolites, MAs III and DMAs III , which were found to be more potent than iAs III as inhibitors of GSIS in isolated pancreatic islets (Douillet et al. 2013 ). Our results suggest that both acute and 24-h exposures to iAs III and MAs III diminish GSIS in β cells by inhibiting oxygen-dependent mitochondrial metabolism, and that both arsenicals target the pathways of pyruvate metabolism in mitochondria. Notably, though previously shown to be an inhibitor of GSIS in intact islets, DMAs III inhibited GSIS in INS-1 832/13 cells only in acute experiments using potentially cytotoxic concentrations and had no significant effects on oxygen consumption under either acute or a 24-h exposure scenario.
Materials and methods

Cell culture
Rat insulinoma cells expressing human pre-proinsulin, INS-1 832/13 (Hohmeier et al. 2000) , were cultured at 5% CO 2 and 37 °C in RPMI 1640 medium supplemented with 10% FBS, 10 mM HEPES, 2 mM l-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin (all from Gibco, Waltham, MA), and 0.05 mM β-mercaptoethanol (Sigma, St. Louis, MO). 
Treatment
GSIS
INS-1 832/13 cells were seeded at a density of 100,000 cells/ well in a 96-well plate 24 h prior to treatment with arsenicals. Following arsenical treatment, cells were placed in a secretion assay buffer (SAB), pH 7.4, containing 114 mM NaCl, 4.7 mM KCl, 1.2 mM KH 2 PO 4 , 1.16 mM MgSO 4 , 20 mM Hepes, 2.5 mM CaCl 2 , 0.2% bovine serum albumin, 25.5 mM NaHCO 3 , and 0 mM glucose for 40 min. Cells were then incubated in 2.5 mM glucose SAB for 1 h. Finally, cells were incubated 2 h in 16.7 mM glucose SAB. For acute arsenic exposures and exposure to mitochondrial inhibitors, INS-1 832/13 cells were seeded at a density of 1,000,000 cells/well in a 12-well plate or at 100,000 cells/ well in a 96-well plate, respectively, 48 h prior to the GSIS assay. The cells were then incubated in 0 mM glucose SAB for 40 min followed by a 1-h incubation in 2.5 mM glucose SAB. Next, the cells were incubated in 16.7 mM glucose containing either arsenicals, as indicated, or uncouplers or inhibitors of the electron transport chain in mitochondria. In both experiments, medium was collected for the 2.5 and 16.7 mM glucose incubation and cells were lysed for protein normalization. The amount of insulin secreted from cells into the media was determined using a Rat/Mouse Insulin ELISA (Millipore, Billerica, MA).
Oxygen consumption rate (OCR) measurement
INS-1 832/13 cells were seeded at a density of 50,000 cells/ well in a Seahorse XFe96 well plate 24 h prior to treatment with arsenicals. Following 24-h arsenic treatment, cells were incubated in 0 mM glucose SAB for 40 min in a 5% CO 2 , 37 °C incubator, followed by incubation in 2.5 mM glucose SAB (without NaHCO 3 ) for 1 h without supplementation of CO 2 at 37 °C. The plate was then placed in the Seahorse XFe96 analyzer (Agilent, Santa Clara, CA) and either 16.7 mM glucose or 10 mM pyruvate was added following baseline OCR measurements. For the mitochondrial stress test, INS-1 832/13 cells treated with arsenicals and untreated cells were incubated in 0 and 2.5 mM glucose SAB as above, then 16.7 mM glucose was added and OCR measured for 30 min. Next, 2 µM oligomycin, 4 µM FCCP (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone), and a 1 µM mix of rotenone/antimycin A (all from Sigma, St. Louis, MO) were added sequentially with 18-min OCR reads in between each addition. For acute exposures, INS-1 832/13 cells were incubated in 0 and 2.5 mM glucose SAB as above, then 16.7 mM glucose was added and OCR monitored for 18 min. Next, each arsenical was added at indicated concentrations and OCR was monitored for 2 h.
Cell viability: MTT assay
INS-1 832/13 cells were seeded at a density of 100,000 cells/ well in a 96-well plate 24 h prior to treatment with arsenicals. Following 24-h (24 h) or acute (2-h) treatment, cells were incubated with 0.5 mg/ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) for 1 h in phenol red free RPMI 1640 cell culture medium. Medium was removed, cells were lysed with DMSO, and absorbance at 570 nm was recorded by a Synergy HT plate reader (Biotek, Winooski, VT).
Cell viability: CellTox™ green assay
INS-1 832/13 cells were seeded at a density of 100,000 cells/ well in a 96 well plate. 24 h after plating, arsenicals were added along with CellTox™ Green Dye using the express, no-step addition at dosing method for the CellTox™ Green Cytotoxicity Assay (Promega, Madison, WI). Fluorescence at 485 Ex /520 EM was measured at 0.5, 1, 2, and 24 h following addition of arsenicals in a Synergy HT plate reader. Between each time point assessment, cell plates were returned to normal cell culture incubation conditions as described above.
Analysis of arsenic
The speciation analysis of arsenic using hydride generation-cryotrapping-atomic absorption spectrometry was performed to determine arsenic content and chemical forms in INS-1 832/13 cells exposed to trivalent arsenicals. The detection limits of the method, calibration procedures and methods used for quality assurance have been previously described (Hernández-Zavala et al. 2008 ).
Statistics
Data were analyzed using a one-or two-way Anova with Dunnet's post-test comparison or student's t test. Data are represented as mean ± standard error of the mean (SEM) or as mean ± standard deviation (SD) as indicated; p values less than 0.05 are statistically significant. Statistical analyses were performed using GraphPad Prism version 7.0 (GraphPad Software Inc., California).
Results
Effects of acute arsenical exposures on OCR and GSIS
OCR was measured for 2 h following addition of iAs III , MAs III , or DMAs III to the INS-1 832/13 cell monolayer in high glucose (16.7 mM) SAB medium. The addition of iAs III (5 or 10 µM) or MAs III (0.375-2 µM) triggered a dose-dependent decrease in OCR that continued during the 2-h exposure window (Fig. 1a, b) . In contrast, addition of DMAs III (up to 10 µM) had no significant effect on OCR (Fig. 1c) . The effects of the acute exposure on GSIS were also examined. Insulin secretion was measured in INS-1 832/13 cells cultured in high glucose medium and exposed for 2, 4 and 6 h to 10 µM iAs III , 2 µMAs III , or 10 µM DMAs III . Exposures to iAs III and MAs III significantly inhibited GSIS (Fig. 1d ), starting at 2 and 4 h, respectively. Surprisingly, a marked inhibition was also observed in cells exposed to 10 µM DMAs III , the concentration that had no effect on OCR (Fig. 1d) .
Effects of 24-h exposures on OCR
OCR was measured in INS-1 832/13 cells exposed for 24 h to iAs III , MAs III , or DMAs III . Two energetic substrates, glucose and pyruvate, were used to stimulate mitochondrial respiration to determine whether the glycolytic pathway in the cytoplasm or mitochondrial pathways (e.g., Krebs Cycle or oxidative phosphorylation) are targeted by the arsenicals. Exposure to iAs III resulted in a dose-dependent decrease in OCR in both low glucose (2.5 mM) and high glucose (16.7 mM) media; however, this decrease was only significant in cells exposed to 2 μM iAs III (Fig. 2a, b) . Essentially the same dose-dependent inhibition of OCR by iAs III was also found in cells stimulated with pyruvate (Fig. 2c, d ). MAs III (0.2-0.5 µM) also inhibited glucose-and pyruvatestimulated OCR in a dose-dependent manner, and it was a more potent inhibitor than iAs III in all experimental conditions (Fig. 3) . The 24-h exposure to DMAs III (up to 2 µM) had no statistically significant effects on OCR in cells stimulated with either glucose or pyruvate (Suppl. Figure 1) .
Effects of 24-h exposure on mitochondrial respiration parameters
The mitochondrial stress test was performed to further assess the effects of arsenicals on β-cell function. Here, OCR was measured in glucose-stimulated INS-1 832/13 cells exposed for 24 h to arsenicals and in the control cells before and after a sequential addition of oligomycin (ATP synthase inhibitor), FCCP (uncoupler), and rotenone with antimycin A (inhibitors of complex I and III, respectively). Maximal respiration (i.e., respiration in presence of the uncoupler FCCP), spare respiratory capacity, non-mitochondrial respiration, and proton leak were assessed following the established procedures and formulas (for details see Suppl. Figure 2 ). Interestingly, maximal respiration was decreased following exposure to all concentrations of iAs III , and was independent of a change in basal OCR at the 0.5 and 1 µM exposure levels (Fig. 4a) . 24-h exposure to 0.375 or 0.5 µM MAs III also elicited a significant reduction in maximal respiration (Fig. 4a) . A significant reduction in spare respiratory capacity was observed following 24-h exposure to all concentrations of iAs III and to 0.5 µM MAs III (Fig. 4b ) and was consistent with the decrease in maximal respiration. Nonmitochondrial respiration was not significantly altered by either iAs III or MAs III exposure (Fig. 4c) . However, proton leak was decreased for most exposures (Fig. 4d) . (Fig. 1d ), we performed a GSIS assay in INS-1 832/13 cells after 24-h exposures. Consistent with results of the acute experiments, 24-h exposure to iAs III inhibited GSIS in a dosedependent manner, but as observed with 24-h OCR inhibition, the inhibition of GSIS was statistically significant only in cells exposed to 2 μM iAs III (Fig. 5a) . Similarly, MAs III suppressed GSIS at the concentrations that also inhibited OCR (0.375 and 0.5 μM) (Fig. 5b) . The 24-h exposure of up to 2 µM DMAs III , unlike the acute exposure to 10 µM DMAs III , had no statistically significant impact on GSIS (Fig. 5c) . As a proof of concept, we have also examined insulin secretion by INS-1 832/13 cells that were exposed to oligomycin and rotenone, two inhibitors used in the mitochondrial stress experiments. Here, 2-h exposures to either oligomycin or rotenone resulted in a marked inhibition of GSIS (Suppl. Figure 3) , confirming that GSIS in these cells is indeed linked to mitochondrial respiration and ATP synthesis.
Effects of 24-h exposures and Mitochondrial
Arsenic speciation in INS-1 832/13 Cells after 24-h exposures
Speciation analysis of arsenic was performed in the INS-1 832/13 cells exposed for 24 h to iAs III , MAs III , or DMAs III . The majority of arsenic found in the cells (> 98%) was represented by species to which the cells were exposed, suggesting that INS-1 832/13 cells cannot methylate or demethylate trivalent arsenicals (Suppl. Table 1 ).
Cell viability after exposure to arsenicals
Two separate assays were used to evaluate viability of INS-1 832/13 cells exposed to trivalent arsenicals: the MTT assay, which measures the metabolic fitness of cells (Janjic and Wollheim 1992) , and the CellTox™ Green assay, which measures cell membrane integrity and is closely linked to cell death (Koen et al. 2016 recorded at low glucose (2.5 mM), high glucose (16.7 mM), and pyruvate (10 mM) were averaged to quantify the overall effects of the exposure. Mean + SEM is shown for four biological replicates. *p < 0.05, + p < 0.01 for comparisons of treated versus untreated (0 μM) cells cells exposed for 24 h to 0.2, 0.375, or 0.5 μM MAs III , but no statistically significant effects were found for iAs III or DMAs III exposure (Fig. 6) . A significant decrease in metabolic activity was also found in cells exposed acutely (for 2 h) to 5 or 10 μM iAs III or 0.5 or 2 μM MAs III , but not in cells exposed to up to 10 μM DMAs III (Suppl. Figure 4 ). Using the CellTox™ Green assay, no significant effects on cell viability were found during the acute (0.5, 1, or 1.5 h) exposures to up to 10 μM iAs III , 2 μM MAs III , or 10 μM DMAs III (Fig. 7) . However, 24-h exposures to ≥ 5 μM iAs III , ≥ 1 μM MAs III , or ≥ 2 μM DMAs III decreased INS-1 832/13 cell viability (Fig. 7) ; notably, OCR was inhibited by lower concentrations.
Discussion
iAs is a multi-target toxin that acts through a variety of mechanisms. In various cell types, exposure to iAs III has been linked to defects in mitochondrial function, including damage to mitochondrial DNA, increased production of reactive oxygen species, decreased expression of Krebs cycle enzymes, and decreased mitochondrial membrane potential (Partridge et al. 2007; Sumedha and Miltonprabu 2015; Prakash et al. 2015 ). Fu and coworkers were the first to show that a prolonged (96-h ) iAs III exposure suppresses mitochondrial respiration in the INS-1 832/13 β-cell line while inhibiting GSIS (Fu et al. 2010 ). These effects were associated with increased transcription of antioxidant genes and suppression of reactive oxygen species (ROS), suggesting that the GSIS inhibition was a result of downregulation of intracellular ROS which may be required for GSIS regulation. These researchers did not identify targets of iAs III in either the cytosolic or mitochondrial pathways of glucose metabolism. Additionally, no effects were examined of the methylated metabolites of iAs, MAs III and have been shown in our studies to inhibit GSIS in isolated islets (Douillet et al. 2013) .
To address these gaps in knowledge, our study focused on OCR as an indirect measure of mitochondrial metabolism, which plays an essential role in regulating GSIS in β cells. We found that trivalent arsenicals, specifically iAs III and MAs III , inhibit OCR in clonal INS-1 832/13 β cells at concentrations that also inhibit GSIS. Notably, the degree of inhibition in the INS-1 832/13 cells stimulated with glucose was similar to that found in the cells stimulated with a metabolite of glucose, pyruvate. Supplementing INS-1 832/13 cells with pyruvate, did not rescue the OCR inhibition by iAs III and MAs III , suggesting that these arsenicals target pyruvate decarboxylation or metabolic steps downstream from this reaction, possibly Krebs cycle or electron transport which are coupled with oxygen consumption. Surprisingly, DMAs III , which was a potent inhibitor of GSIS in intact isolated islets in our previous study (Douillet et al. 2013) , did not inhibit either GSIS or OCR in the cultured INS-1 832/13 cells in the 24-h exposure experiments and inhibited only GSIS in the acute exposure experiments at high doses (10 μM). Differences in the results of the isolated islets and β-cell line may be due to the composition of islets in that they are of multiple cell types and the cell-to-cell crosstalk is essential for synchronization of insulin secretion from the β cells (Yang et al. 2011; Caicedo 2013) . Thus, while not directly affecting β cells, DMAs III may target the mechanisms involved in the cell-to-cell communication leading to an impairment of GSIS in intact islets. Furthermore, the requirement for the thiol-reactive reagent β-mercaptoethanol in the culture medium of INS-1 832/13 cells may impact the action of arsenicals in the cell, especially DMAs III , which can bind with high affinity to the single thiol group of β-mercaptoethanol (Shen et al. 2013 ). An additional factor that plays a role in experiments involving DMAs III exposure is the low stability of this arsenical; DMAs III readily oxidizes to a non-toxic pentavalent analog, DMAs V (Gong et al. 2001 ). Thus, it is possible that DMAs III oxidized during the 24-h exposures allowing the β cells in culture to recover and to restore both mitochondrial respiration and GSIS. This would also explain why the short-acute exposure to DMAs III did inhibit GSIS. However, the fact that the acute exposure did not affect OCR suggests that mechanisms other than mitochondrial dysfunction may underlie GSIS inhibition by this arsenical.
Interestingly, both iAs III and MAs III inhibited maximal mitochondrial respiration (i.e., oxygen consumption in presence of an uncoupler) and spare respiratory capacity, suggesting a direct effect on electron carriers of the electron transport chain in the inner mitochondrial membrane. This finding is consistent with the previously reported inhibition of the mitochondrial electron transport in rat RLC-16 liver cells exposed to the trivalent arsenicals (Naranmandura et al. 2011) . Conversely, there is no significant difference in nonmitochondrial respiration between any treatment groups, suggesting that the mitochondria are the primary targets and that OCR inhibition by the arsenicals is exclusively due to suppression of mitochondrial respiration. In other studies, arsenicals have been shown to inhibit essential reactions that feed into the electron transport chain including pyruvate dehydrogrenase, succinate dehydrogenase, α-ketoglutarate dehydrogenase, among other components of the Krebs cycle, which could generate a similar outcome of reduced OCR as observed in the present study (Petrick et al. 2001; Bergquist et al. 2009; Hosseini et al. 2013) . In either scenario, iAs III and MAs III appear to inhibit either the reactions that feed into the electron transport chain or the electron transport chain itself.
In the present study, MAs III was more potent than iAs III as an inhibitor of OCR in INS-1 832/13 β cells. These findings are consistent with the results of another study conducted in vascular smooth muscle cells, which showed a decrease in OCR after exposure to 0.5 μM MAs III , whereas exposure to 10 μM iAs III had no significant effect on OCR (Pace et al. Although results of the present study strongly suggest that iAs III and MAs III impair mitochondrial function leading to impaired GSIS, the implications for human exposures and the development of diabetes remain unclear. There is no data on the concentrations of iAs or its methylated metabolites in pancreata of humans chronically exposed to iAs. Although β-cell dysfunction has been reported in individuals exposed to iAs (Del Razo et al. 2011; Gribble et al. 2012; Díaz-Villaseñor et al. 2013; Rhee et al. 2013; Peng et al. 2015) , it is unclear if it was associated with β-cell loss or with impaired β-cell function. Our results suggest that to inhibit mitochondrial function, the concentrations of trivalent arsenicals would need to reach micromolar or sub-micromolar levels that may be toxic to β cells. The results of the CellTox™ Green membrane integrity assay show no or minor losses of cell viability at exposure levels that inhibited OCR in INS-1 832/13 cells. The MTT assay, which measures metabolic activity of the cells, suggests a reduction in the metabolic activity following 24-h exposure to MAs III . However, it has been previously reported that inhibition of metabolic activity as recorded by the MTT assay preceded any appreciable change in cell viability (cell death) (Green and Leeuwenburgh 2002 (Styblo et al. 2000) . Additionally, we see no appreciable loss of cell membrane integrity during the acute exposure, where OCR was significantly inhibited by very short exposures to iAs III or MAs III . The OCR inhibition under these conditions cannot be explained by changes in gene transcription, as suggested in Fu et al. (2010) , but points again to direct interactions of the arsenicals with metabolic pathways that are linked to glucose metabolism and/or OCR. Overall, the results of the MTT assay performed in INS-1 832/13 cells combined with the results of the Seahorse XF assay are consistent with inhibition of mitochondrial metabolism and do not necessarily indicate cell death. More data on the concentrations of iAs and its metabolites in human tissues are needed to help to better explain the results of this study and to inform designs of future mechanistic studies examining effects of in vitro exposures of iAs in cultured cells or tissues.
In summary, this study is the first to compare the effects of iAs III and its methylated trivalent metabolites, DMAs III and MAs III , on GSIS and OCR in a pancreatic β-cell model. The results suggest that inhibition of OCR by iAs III and/or MAs III may be one of the mechanisms by which iAs exposure impairs β-cell function, leading to diabetes in humans. Future studies should identify the specific metabolic steps and mechanisms that are targeted by iAs and its metabolites in β cells. Results of these studies may ultimately help to improve the understanding of how iAs affects mitochondria not only in β cells, but also in other cell types that regulate glucose homeostasis. Knowledge of the precise mechanisms underlying the diabetogenic effects of iAs and its metabolites could improve treatment strategies for diabetes associated with iAs exposure. 
